Global Heart Failure Drugs Market 2021-2025

Global Heart Failure Drugs Market 2021-2025

Technavio has been monitoring the heart failure drugs market and it is poised to grow by $ 2.69 bn during 2021-2025, progressing at a CAGR of 7.75% during the forecast period. Our report on the heart failure drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population and increase in chronic diseases. In addition, rising geriatric population is anticipated to boost the growth of the market as well.

The heart failure drugs market analysis includes the drug-class segment and geographic landscape.

Technavio's heart failure drugs market is segmented as below:

By Drug-class

• Beta-blockers
• ARBs
• ACE inhibitors
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies sedentary lifestyles as one of the prime reasons driving the heart failure drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on heart failure drugs market covers the following areas:

• Heart failure drugs market sizing
• Heart failure drugs market forecast
• Heart failure drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading heart failure drugs market vendors that include Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Exelixis Inc., Gilead Sciences Inc., Novartis AG, and Pfizer Inc. Also, the heart failure drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Exelixis Inc., Gilead Sciences Inc., Novartis AG, Pfizer Inc.